Adherence and Persistence with Once-Daily Teriparatide in Japan: A Retrospective, Prescription Database, Cohort Study

Adherence and persistence with osteoporosis treatments are essential for reducing fracture risk. Once-daily teriparatide is available in Japan for treating osteoporosis in patients with a high risk of fracture. The study objective was to describe real-world adherence and persistence with once-daily...

Full description

Saved in:
Bibliographic Details
Main Authors: Ikuko Tanaka, Masayo Sato, Tomoko Sugihara, Douglas E. Faries, Shuko Nojiri, Peita Graham-Clarke, Jennifer A. Flynn, Russel T. Burge
Format: Article
Language:English
Published: Wiley 2013-01-01
Series:Journal of Osteoporosis
Online Access:http://dx.doi.org/10.1155/2013/654218
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850165831404617728
author Ikuko Tanaka
Masayo Sato
Tomoko Sugihara
Douglas E. Faries
Shuko Nojiri
Peita Graham-Clarke
Jennifer A. Flynn
Russel T. Burge
author_facet Ikuko Tanaka
Masayo Sato
Tomoko Sugihara
Douglas E. Faries
Shuko Nojiri
Peita Graham-Clarke
Jennifer A. Flynn
Russel T. Burge
author_sort Ikuko Tanaka
collection DOAJ
description Adherence and persistence with osteoporosis treatments are essential for reducing fracture risk. Once-daily teriparatide is available in Japan for treating osteoporosis in patients with a high risk of fracture. The study objective was to describe real-world adherence and persistence with once-daily teriparatide 20 μg during the first year of treatment for patients who started treatment during the first eight months of availability in Japan. This prescription database study involved patients with an index date (first claim) between October 2010 and May 2011, a preindex period ≥6 months, and a postindex period ≥12 months and who were aged >45 years. Adherence (medication possession ratio (MPR)) and persistence (time from the start of treatment to discontinuation; a 60-day gap in supply) were calculated. A total of 287 patients started treatment during the specified time period; 123 (42.9%) were eligible for inclusion. Overall mean (standard deviation) adherence was 0.702 (0.366), with 61.0% of patients having high adherence (MPR > 0.8). The percentage of patients remaining on treatment was 65.9% at 180 days and 61.0% at 365 days. Our findings suggest that real-world adherence and persistence with once-daily teriparatide in Japan are similar to that with once-daily teriparatide in other countries and with other osteoporosis medications.
format Article
id doaj-art-e1d3b5cbf195444dab8b0f2ffb4c9682
institution OA Journals
issn 2090-8059
2042-0064
language English
publishDate 2013-01-01
publisher Wiley
record_format Article
series Journal of Osteoporosis
spelling doaj-art-e1d3b5cbf195444dab8b0f2ffb4c96822025-08-20T02:21:38ZengWileyJournal of Osteoporosis2090-80592042-00642013-01-01201310.1155/2013/654218654218Adherence and Persistence with Once-Daily Teriparatide in Japan: A Retrospective, Prescription Database, Cohort StudyIkuko Tanaka0Masayo Sato1Tomoko Sugihara2Douglas E. Faries3Shuko Nojiri4Peita Graham-Clarke5Jennifer A. Flynn6Russel T. Burge7Nagoya Rheumatology Clinic/Initiative for Rheumatology and Osteoporosis, Nagoya 4500002, JapanLilly Research Laboratories Japan, Eli Lilly Japan K.K., 7-1-5 Isogami dori, Chuoku, Kobe 6510086, JapanStatistical Programming, PharmaNet/i3 LLC, Indianapolis, IN 46280, USAStatistics, Eli Lilly and Company, Indianapolis, IN 46285, USASurveillance & Epidemiology, Global Patient Safety Japan, Eli Lilly Japan K.K., Kobe 6510086, JapanGlobal Health Outcomes, Eli Lilly Australia Pty Ltd, Sydney 2114, AustraliaLilly Research Laboratories Japan, Eli Lilly Japan K.K., 7-1-5 Isogami dori, Chuoku, Kobe 6510086, JapanGlobal Health Outcomes, Eli Lilly and Company, Indianapolis, IN 46285, USAAdherence and persistence with osteoporosis treatments are essential for reducing fracture risk. Once-daily teriparatide is available in Japan for treating osteoporosis in patients with a high risk of fracture. The study objective was to describe real-world adherence and persistence with once-daily teriparatide 20 μg during the first year of treatment for patients who started treatment during the first eight months of availability in Japan. This prescription database study involved patients with an index date (first claim) between October 2010 and May 2011, a preindex period ≥6 months, and a postindex period ≥12 months and who were aged >45 years. Adherence (medication possession ratio (MPR)) and persistence (time from the start of treatment to discontinuation; a 60-day gap in supply) were calculated. A total of 287 patients started treatment during the specified time period; 123 (42.9%) were eligible for inclusion. Overall mean (standard deviation) adherence was 0.702 (0.366), with 61.0% of patients having high adherence (MPR > 0.8). The percentage of patients remaining on treatment was 65.9% at 180 days and 61.0% at 365 days. Our findings suggest that real-world adherence and persistence with once-daily teriparatide in Japan are similar to that with once-daily teriparatide in other countries and with other osteoporosis medications.http://dx.doi.org/10.1155/2013/654218
spellingShingle Ikuko Tanaka
Masayo Sato
Tomoko Sugihara
Douglas E. Faries
Shuko Nojiri
Peita Graham-Clarke
Jennifer A. Flynn
Russel T. Burge
Adherence and Persistence with Once-Daily Teriparatide in Japan: A Retrospective, Prescription Database, Cohort Study
Journal of Osteoporosis
title Adherence and Persistence with Once-Daily Teriparatide in Japan: A Retrospective, Prescription Database, Cohort Study
title_full Adherence and Persistence with Once-Daily Teriparatide in Japan: A Retrospective, Prescription Database, Cohort Study
title_fullStr Adherence and Persistence with Once-Daily Teriparatide in Japan: A Retrospective, Prescription Database, Cohort Study
title_full_unstemmed Adherence and Persistence with Once-Daily Teriparatide in Japan: A Retrospective, Prescription Database, Cohort Study
title_short Adherence and Persistence with Once-Daily Teriparatide in Japan: A Retrospective, Prescription Database, Cohort Study
title_sort adherence and persistence with once daily teriparatide in japan a retrospective prescription database cohort study
url http://dx.doi.org/10.1155/2013/654218
work_keys_str_mv AT ikukotanaka adherenceandpersistencewithoncedailyteriparatideinjapanaretrospectiveprescriptiondatabasecohortstudy
AT masayosato adherenceandpersistencewithoncedailyteriparatideinjapanaretrospectiveprescriptiondatabasecohortstudy
AT tomokosugihara adherenceandpersistencewithoncedailyteriparatideinjapanaretrospectiveprescriptiondatabasecohortstudy
AT douglasefaries adherenceandpersistencewithoncedailyteriparatideinjapanaretrospectiveprescriptiondatabasecohortstudy
AT shukonojiri adherenceandpersistencewithoncedailyteriparatideinjapanaretrospectiveprescriptiondatabasecohortstudy
AT peitagrahamclarke adherenceandpersistencewithoncedailyteriparatideinjapanaretrospectiveprescriptiondatabasecohortstudy
AT jenniferaflynn adherenceandpersistencewithoncedailyteriparatideinjapanaretrospectiveprescriptiondatabasecohortstudy
AT russeltburge adherenceandpersistencewithoncedailyteriparatideinjapanaretrospectiveprescriptiondatabasecohortstudy